Remix Therapeutics™ Announces Publication in Science that Reveals Unprecedented Insights into Spliceosome Regulation and Alternative Splicing
WATERTOWN, Mass., Oct. 31, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced